Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		An Open-Label, Single-Center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				AT-101-CS-102 NCT00561197


2.		A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				AT-101-CS-205 NCT00571675

Last Modified: 11/21/2008 First Published: 4/23/2008


3.		Phase II Study of R-(-)-Gossypol (AT-101) and Androgen Ablation Therapy in Patients With Newly Diagnosed Metastatic Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				CINJ-080707 080707, 8014, CINJ-0220080008, NCT00666666

Last Modified: 11/20/2008 First Published: 10/14/2008


4.		Phase II Study of R-(-)-gossypol in Patients With Recurrent Extensive Stage Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MAYO-MC0721 MC0721, 8027, NCT00773955

Last Modified: 5/29/2008 First Published: 10/10/2007


5.		Phase I Study of R-(-)-Gossypol, Cisplatin, and Etoposide in Patients With Advanced, Refractory Solid Tumors or Extensive Stage Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				WCCC-CO-07901 8062, CO 07901, NCT00544596

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute